Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Design Therapeutics, Inc. (DSGN)
A forensic read on Design Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
12.1
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-33.1%
ROE
$834M
Market cap
Design Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 12.1, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-32%Return on invested capital.Return on invested capital is -32% and slipping from -18% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+1.0%/yrShare-count dilution.Diluted share count changed +3% over the last 3 years to FY2025 (+1.0%/yr). Roughly flat — buybacks are about offsetting stock comp, not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
Key fundamentals
Free Cash Flow$-54.6M
Return on Equity-32.8%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Design Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about DSGN's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown